| Business Summary | | Discovery
Partners
International
Inc.
develops
and
sells
instruments
and
associated
consumables
to
pharmaceutical
companies
for
the
generation
of
chemical
compounds
for
drug
discovery.
The
Company
sells
products
and
services
designed
to
make
the
drug
discovery
process
faster,
less
expensive
and
more
likely
to
generate
a
drug
candidate.
The
products
and
services
provided
by
the
Company's
four
principal
product
groups,
ChemRx
Advanced
Technologies,
Discovery
Technologies,
IRORI
and
Structural
Proteomics,
can
be
purchased
individually
or
as
integrated
solutions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Discovery
Partners
International,
Inc.
develops
and
sells
instruments
and
associated
consumables
to
pharmaceutical
companies
for
the
generation
of
chemical
compounds
to
be
used
in
drug
discovery.
For
the
six
months
ended
6/30/01,
revenues
rose
40%
to
$20.6
million.
Net
loss
fell
72%
to
$3.1
million.
Results
reflect
the
acquisitions
of
Axys
Advanced
Technologies
and
Systems
Integration
Drug
Discovery
and
the
absence
of
a
$9
million
write-off
R&D
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Riccardo Pigliucci, 54 Chairman,
Pres, CEO | $598K | -- | Jack Fitzpatrick, 46 CFO,
VP of Fin. and Admin., Sec. | 269K | $352K | Richard Brown, Ph.D., 48 Pres,
IRORI | 264K | 275K | David Coffen, Ph.D., 62 CSO | 278K | -- | John Lillig, 51 Chief
Technologist | 230K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|